In yesterday’s Wall Street session, Amedisys Inc. (NASDAQ:AMED) shares traded at $91.35, down -0.10% from the previous session.
As of this writing, 14 analysts cover Amedisys Inc. (NASDAQ:AMED). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $115.00 and a low of $73.00, we find $100.50. Given the previous closing price of $91.44, this indicates a potential upside of 9.91 percent. AMED stock price is now 10.12% away from the 50-day moving average and 4.09% away from the 200-day moving average. The market capitalization of the company currently stands at $2.98B.
There are 9 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $97.42 as their price target over the next twelve months.
With the price target maintained at $97, Truist recently Downgraded its rating from Buy to Hold for Amedisys Inc. (NASDAQ: AMED).
In other news, North Michael Paul, Chief Information Officer sold 5,908 shares of the company’s stock on Mar 03. The stock was sold for $510,628 at an average price of $86.43. Upon completion of the transaction, the Chief Information Officer now directly owns 4,164 shares in the company, valued at $0.38 million. Insiders disposed of 36,984 shares of company stock worth roughly $3.38 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMED stock. A new stake in Amedisys Inc. shares was purchased by ALYESKA INVESTMENT GROUP, L.P. during the first quarter worth $25,803,000. EVERSEPT PARTNERS, LP invested $20,486,000 in shares of AMED during the first quarter. In the first quarter, GREAT LAKES ADVISORS, LLC acquired a new stake in Amedisys Inc. valued at approximately $12,547,000. MARSHALL WACE, LLP acquired a new stake in AMED for approximately $8,340,000. TEKLA CAPITAL MANAGEMENT LLC purchased a new stake in AMED valued at around $6,298,000 in the second quarter. In total, there are 396 active investors with 98.14% ownership of the company’s stock.
Monday morning saw Amedisys Inc. (NASDAQ: AMED) opened at $91.45. During the past 12 months, Amedisys Inc. has had a low of $69.36 and a high of $131.32. As of last week, the company has a debt-to-equity ratio of 0.37, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for AMED is $82.96 and a two-hundred day moving average price translates $87.76 for the stock.
The latest earnings results from Amedisys Inc. (NASDAQ: AMED) was released for Mar, 2023. According to the Medical Care Facilities Company, earnings per share came in at $1, beating analysts’ expectations of $0.88 by 0.12. This compares to $0.97 EPS in the same period last year. The net profit margin was 5.00% and return on equity was 10.90% for AMED. The company reported revenue of $556.39 million for the quarter, compared to $545.26 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.04 percent. For the current quarter, analysts expect AMED to generate $568.2M in revenue.
Amedisys Inc.(AMED) Company Profile
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer’s. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
